Mounjaro®
Starting from £179.99/mo
Start journey Learn moreThere is no official Wegovy food list PDF from Novo Nordisk or the NHS — but the clinical trials and licensed prescribing guidance do point clearly to the eating patterns that support semaglutide treatment. Wegovy (semaglutide) is a prescription-only medicine requiring a clinical assessment before it can be prescribed, and the dietary advice that accompanies it is personalised, not a one-size download. That said, the evidence behind what to eat while appetite is suppressed is consistent enough to lay out plainly here.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The appeal of a downloadable food list is obvious. You start a new medicine, appetite shifts overnight, and you want a cheat sheet for the fridge door. The problem is that no such document exists as an official resource because semaglutide's licensed use specifies a reduced-calorie diet alongside increased physical activity, without prescribing the diet itself. Wegovy's SmPC on the electronic Medicines Compendium sets out the clinical criteria, not a meal plan.
What the STEP 1 trial, published in the New England Journal of Medicine, did measure was average weight reduction of around 15% over 68 weeks, achieved alongside a structured lifestyle programme. That programme emphasised consistent, moderate caloric reduction and regular activity. The trial did not endorse one specific diet pattern, which is part of why no canonical list followed.
The practical answer is that the foods most supported by evidence for people on GLP-1 medicines cluster around a few principles: adequate protein, fibre-rich carbohydrates, modest fat portions, and steady hydration. Our detailed Wegovy food list covers those principles with specific food examples if you want a more structured reference.
Semaglutide slows gastric emptying and reduces appetite substantially. That creates two practical risks: eating too little protein (because overall intake falls), and triggering nausea by eating foods that already sit heavily in the stomach. The foods that tend to work well address both.
Lean protein sources (chicken, fish, eggs, low-fat dairy, legumes) are consistently recommended alongside GLP-1 treatment because muscle tissue is metabolically active and the weight lost in trials includes fat and lean mass in roughly similar proportions without deliberate effort to preserve protein intake. Prioritising protein at each meal is the single most practical nutritional instruction that emerges from the evidence.
Fibre-rich foods (vegetables, wholegrains, pulses) slow digestion gently, support gut health, and tend to improve the constipation that some people experience on semaglutide. The full breakdown of foods to eat on semaglutide explains this in more detail, including portion guidance.
Foods that frequently cause problems: very fatty or fried meals, carbonated drinks (bloating can worsen nausea), and large single servings when appetite is already low. Alcohol interacts with the hypoglycaemic risks in diabetic contexts and adds empty calories; it is worth discussing with your prescriber if you drink regularly.
For practical meal structuring ideas, our Wegovy meal plan guide translates these principles into day-by-day examples.
The oral Wegovy tablet (approved by the MHRA in June 2026 as the first oral GLP-1 licensed for weight management in the UK) adds one specific dietary consideration that the injection does not: it must be taken first thing in the morning on an empty stomach with a small sip of plain water, and you need to wait at least 30 minutes before eating, drinking anything other than water, or taking other oral medicines. That waiting window is about absorption, the tablet relies on it. Many people find it easier to build this into an existing routine: tablet before the kettle even goes on, breakfast 30 to 40 minutes later.
Beyond that morning window, the dietary principles are the same for both forms. Protein, fibre, hydration, modest portions, avoiding very fatty foods during dose increases. The NHS semaglutide page covers the medicine's general dietary context at nhs.uk/medicines/semaglutide.
If you are considering switching from the injection to the tablet, or are on the tablet and finding your appetite suppression differs from what you expected, the right conversation is with your prescriber rather than a food list. Our guide to eating on Wegovy also covers the transition context.
A food list is a starting point, not a substitute for oversight. Wegovy is a prescription-only medicine, and the dietary advice that sits alongside it is most useful when a prescriber knows your full picture: your current weight, any conditions affecting how you absorb food, medicines that might interact, and your realistic daily routine. Generic guidance cannot do that.
Cost is sometimes what stops people asking. For context on what private treatment actually involves financially, our Wegovy pricing page sets out what a transparent private prescription includes. There is more on how Wegovy works as a treatment if you are still at the research stage.
If semaglutide is not right for you, or you want to compare options, our weight-loss treatments overview covers what is currently licensed in the UK. Speak to our prescribers to get a personalised view on what dietary approach fits your treatment plan.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.